Canaccord analyst Kyle Rose raised his price target on NuVasive to $80 from $70 following meetings with management. The analyst believes the shares offer a compelling risk/reward setup in medtech citing its conservative guidance, robust new product flow, stable U.S. spine market share, and improving investor sentiment. Rose reiterated his Buy rating on NuVasive shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.